Preferred Label : mifamurtide;

MeSH note : protects mice against herpes simplex virus type 2; structure given in first source; RN refers to L-Alaninamide,(R)-isomer; a macrophage activator; called muramyl tripeptide but that term is ambiguous, confused with other tripeptides of muramic acid;

CISMeF synonym : CGP 19835 A; MLV 19835;

MeSH synonym : N-acetylmuramyl-alanyl-isoglutaminyl-alanyl-sn-glycero-3-phosphoethanolamine; muramyl tripeptide phosphatidylethanolamine; muramylNAc-Ala-isoGln-Lys-tripeptide-phosphatidylethanolamine; muramyl tripeptide-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine conjugate; muramyl tripeptide-1,2-dipalmitoylphosphatidylethanolamine conjugate; muramylNAc-Ala-isoGln-Lys-tripeptide-PE;

MeSH hyponym : CGP 19853A lipid; mifamurtide sodium; mifamurtide anhydrous; mifamurtide sodium salt; CGP-19835A; mifamurtide free acid anhydrous;

MeSH CAS label : L-Alaninamide, N-(N-acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-(4-hydroxy-10-oxo-7-((1-oxohexadecyl)oxy)-3,5,9-trioxa-4-phosphapentacos-1-yl)-, P-oxide, (R)-;

MeSH Related Number : muramyl tripeptide phosphatidylethanolamine, sodium salt; muramyl tripeptide phosphatidylethanolamine, monosodium salt; 83461-56-7 (mifamurtide); 83541-33-7 (mono-Na salt); 84277-95-2 (Na salt); 838853-48-8; 21G81IKJ8L; 83461-56-7 (acid); 90825-43-7 (Na salt); EQD2NNX741;

Registry Number MeSH : 83461-56-7;

Related CAS MeSH : 83541-33-7 (muramyl tripeptide phosphatidylethanolamine, monosodium salt); 84277-95-2 (muramyl tripeptide phosphatidylethanolamine, sodium salt);

related registry number list (CISMeF) : 83541-33-7 (mono-Na salt); 84277-95-2 (Na salt);

Is substance : O;

UNII : EQD2NNX741; 1LM890Q4FY;

InChIKey : ZVLWUMPAHCEZAW-KRNLDFAISA-N;

Details


Main resources

You can consult :


https://ansm.sante.fr/informations-de-securite/mepact-4-mg-mifamurtide-attention-au-risque-de-dysfonctionnement-ou-de-fuite-du-filtre-lors-de-la-reconstitution
2020
false
false
false
France
French
mifamurtide
equipment failure analysis
Medical Device Failure or Malfunction
phosphatidylethanolamines
acetylmuramyl-alanyl-isoglutamine
acetylmuramyl-alanyl-isoglutamine

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60782901
2012
France
summary of product characteristics
package leaflet
powders
injections
suspensions
mifamurtide

---
https://www.ema.europa.eu/medicines/human/EPAR/Mepact
2012
United Kingdom
English
French
syndication feed
acetylmuramyl-alanyl-isoglutamine
phosphatidylethanolamines
phosphatidylethanolamines
mifamurtide
mifamurtide
drug approval
treatment outcome
infusions, intravenous
child
adolescent
adult
osteosarcoma
adjuvants, immunologic
adjuvants, immunologic
orphan drug production
rare diseases
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
drug compounding
mifamurtide
package leaflet
summary of product characteristics
drug evaluation

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-12/mepact-_ct-8306.pdf
http://www.has-sante.fr/portail/jcms/c_1007484/mepact
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/mepact_ct_8306.pdf
2011
France
French
English
mifamurtide
acetylmuramyl-alanyl-isoglutamine
phosphatidylethanolamines
mifamurtide
adjuvants, immunologic
orphan drug production
infusions, intravenous
osteosarcoma
child
adolescent
adult
treatment outcome
drug therapy, combination
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_1046160/mepact-mifamurtide-immunomodulateur
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-12/mepact-_ct-8306.pdf
2010
France
French
mifamurtide
phosphatidylethanolamines
acetylmuramyl-alanyl-isoglutamine
adjuvants, immunologic
mifamurtide
child
adolescent
adult
osteosarcoma
antineoplastic combined chemotherapy protocols
treatment outcome
infusions, intravenous
evaluation of the transparency committee
guidelines for drug use

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.